Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)
NCT04888130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44
Last updated 2021-05-17
Summary
Clinical, epidemiological, therapeutic and microbiological investigation of an outbreak of cutaneous Leishmaniasis that occurred among military personnel in French Guiana in 2020.
Conditions
- Leishmaniasis, Cutaneous
Interventions
- GENETIC
-
Phylogenetic Analysis
The phylogenetic analysis is carried out on a sample already taken in routine care (smear, culture on biopsy or PCR on swab).
- OTHER
-
Data collection
Data will be collected using a standardized digital questionnaire, including clinical and microbiological features, treatments received details and training conditions and. Data will then be compared between patients with therapeutic success or failure.
Sponsors & Collaborators
-
Centre Médical Inter-Armées (CMIA) de Cayenne, French Guiana
collaborator UNKNOWN -
Centre Médical Inter-Armées (CMIA) de Kourou, French Guiana
collaborator UNKNOWN -
Direction Interarmées du Service de Santé des Armées (DIASS) de Cayenne, French Guiana
collaborator UNKNOWN -
Centre National de Référence des Leishmanioses, CHU de Montpellier, France
collaborator UNKNOWN -
Centre Hospitalier de Cayenne
lead OTHER
Principal Investigators
-
DEMAR PIERRE Magalie, PhD · Centre Hospitalier de Cayenne
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-12-01
- Primary Completion
- 2021-03-01
- Completion
- 2021-05-07
Countries
- French Guiana
Study Locations
More Related Trials
-
Clinical Prognostic Score to Predict Relapse in VL
NCT05602610 ·Status: RECRUITING
-
Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in Ethiopia
NCT05332093 ·Status: COMPLETED
-
High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus
NCT01953744 ·Status: TERMINATED ·Phase: PHASE3
-
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
NCT03784248 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)
NCT01975051 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
NCT04072874 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis
NCT00973128 ·Status: COMPLETED ·Phase: PHASE2
-
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
NCT05449717 ·Status: COMPLETED
-
Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia
NCT01769612 ·Status: COMPLETED
-
Expression of Mif Alleles in Individuals With Leishmaniasis
NCT00401349 ·Status: COMPLETED
-
Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
NCT01310738 ·Status: TERMINATED ·Phase: PHASE4
-
Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia
NCT02148822 ·Status: COMPLETED
-
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
NCT03303898 ·Status: COMPLETED ·Phase: NA
-
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
NCT01011309 ·Status: COMPLETED ·Phase: PHASE2
-
Liposomal Amphotericin in Disseminated Leishmaniasis
NCT02025491 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite
NCT00121849 ·Status: COMPLETED ·Phase: PHASE1
-
Sero-epidemiology of Priority Arboviruses in French Guiana
NCT03210363 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children
NCT03521973 ·Status: COMPLETED ·Phase: PHASE2
-
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
NCT01988909 ·Status: COMPLETED ·Phase: PHASE2
-
Miltefosine and GM-CSF in Cutaneous Leishmaniasis
NCT03023111 ·Status: COMPLETED ·Phase: PHASE3
-
Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
NCT06000514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
NCT02530697 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis
NCT00317980 ·Status: COMPLETED ·Phase: PHASE4
-
Immune Responses After Human Subject Challenge With Sand Fly Bites
NCT01289977 ·Status: COMPLETED
-
Diagnosis and Treatment of Leishmania Infections
NCT00344188 ·Status: RECRUITING